Jun 22, 2020
MaxCyte to Present at 2020 European Biotech Investor Day
May 18, 2020
MaxCyte to Share Preliminary Phase I Data on MCY-M11 at ASCO 2020 Annual Meeting
May 07, 2020
Caribou Biosciences and MaxCyte Enter into Clinical and Commercial License Agreement
Apr 06, 2020
MaxCyte to Present at Upcoming 2020 Solebury Trout Virtual Investor Conference
Mar 24, 2020
MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to Enable the Advancement of Allogeneic CAR T (AlloCAR T(TM)) Therapies
Dec 19, 2019
MaxCyte Appoints New Executive Vice President, Business Development for CARMA(TM) Cellular Therapies and Provides Clinical Trial Update
May 29, 2019
MaxCyte CEO Doug Doerfler to Present at 2019 BIO International Convention
May 08, 2019
MaxCyte Progresses Phase I Clinical Trial of Lead mRNA-based Cell Therapy from its CARMA(TM) Platform
Apr 08, 2019
MaxCyte® Launches ExPERT(TM) Family of Instruments, Providing a Unifying Technology Platform from Concept to Commercialization for the Next Generation of Cellular Therapies
Nov 21, 2018
MaxCyte to Present at Piper Jaffray 30th Annual Healthcare Conference
Jun 11, 2018
MaxCyte and U.S. National Institutes of Health's National Heart, Lung, and Blood Institute Enter Cooperative Research & Development Agreement for Sickle Cell Disease
May 21, 2018
MaxCyte Reports Preclinical Results at ASGCT Annual Meeting Showing Efficient Correction of Sickle Cell Mutation in Hematopoietic Stem Cells (HSC)
Apr 25, 2018
MaxCyte Appoints Dr. Claudio Dansky Ullmann as Chief Medical Officer
Jun 06, 2017
MaxCyte and National Institute of Allergy and Infectious Diseases to Collaborate on Research for Ultra-Rare Disease Therapy